News

Article

EC Approves Lupkynis for Treatment of Active Lupus Nephritis

Otsuka announced that the EC has approved Lupkynis as the first oral treatment for active lupus nephritis.

Otsuka Pharmaceutical Europe (Otsuka) announced on Sept. 20, 2022 that the European Commission (EC) has approved Lupkynis (voclosporin) in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV, or V lupus nephritis (LN).

The EC decision applies to all 27 European Union member states, as well as Iceland, Norway, Liechtenstein, and Northern Ireland. According to a company press release, voclosporin is the only oral treatment approved in Europe for the treatment of active LN in adult patients.

LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease, and is suggested to cause irreversible nephron loss. According to the press release, up to 210 in 100,000 people in Europe live with SLE, and between 40 and 60 percent of those with SLE are at risk of developing LN during their lifetime.

"Today's EC approval of voclosporin represents a significant development for lupus nephritis patients in Europe, offering the appropriate patients a new treatment option," said Andy Hodge, CEO, Otsuka Pharmaceutical Europe, in the release.

Source: Otsuka

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content